Mutant CD83 promoter and use thereof

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes a genetically engineered (mutant) CD83 promoter that is specifically active in human dendritic cells, particularly in their mature state. By combining specific promoter and enhancer elements from the human CD83 gene, the invention provides a tool for targeted gene expression exclusively in dendritic cells. This technology can be used to direct the expression of desired genes (such as tumor antigens or immunomodulatory molecules) only in dendritic cells, making it valuable for various immunotherapy and vaccine strategies, including cancer therapy, autoimmune disease treatment, and prevention of organ transplant rejection.

Use CasesContent extracted from patent full text and abstract with AI.

• Cancer immunotherapy: To drive dendritic cell-targeted expression of tumor antigens to induce anti-tumor immune responses.
• Autoimmune disease therapy: To locally express immunomodulatory genes in dendritic cells for suppressing undesirable immune reactions.
• Organ or cell transplantation: To limit immune responses specifically in dendritic cells to prevent transplant rejection.
• Vaccine development: To enhance antigen presentation by dendritic cells, boosting vaccine-induced immunity against infectious diseases.
• Development of gene therapy vectors with dendritic cell specificity for controlled delivery of therapeutic genes.

BenefitsContent extracted from patent full text and abstract with AI.

• Highly specific expression in human dendritic cells, especially in their mature state, reducing off-target gene effects.
• Enables precise control of immune system modulation by targeting a master regulator cell type in immunity.
• Improves safety profile of gene therapy and vaccine approaches by restricting gene activation to relevant immune cells.
• Versatile platform technology for a range of immune-related diseases, including cancer, autoimmunity, and transplant medicine.
• Facilitates the development of targeted therapeutics, reducing side effects and enhancing efficacy.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention provides a mutant CD83 promoter comprising the promoter/enhancer regions of human CD83 promoter and being dendritic cell-specific, and the use thereof, specifically for the treatment or prevention of diseases or medical conditions related to malignancy, autoimmunity or prevention of transplant rejections.